Date: 2011-05-06
Type of information: Grant
Company: Opsona Therapeutics (Ireland)
Investors: European Commission’s Seventh Framework Program (FP7)
Amount: €5.9 million
Funding type: grant
Planned used: The specific focus of the Consortium will be the development of OPN-305 as a therapeutic agent for the prevention of Delayed Graft Function (DGF), a serious complication of the immediate postoperative period in renal transplantation. OPN-305 is a monoclonal antibody inhibitor of Toll-like-receptor-2 (TLR-2). Data generated by Opsona, its collaborators and independent scientists has provided solid scientific evidence for a link between TLR-2 and DGF. The consequences of DGF can be prolonged hospitalisation of patients, additional invasive procedures and transplant rejection. There is currently no specific therapeutic treatment for DGF. Following successful completion of the Phase 1 trial this year, the consortium plans to conduct a prospective randomized placebo-controlled Phase 2 trial in the prevention of DGF to be initiated in 2012.
Others: Opsona Therapeutics, has been awarded €5.9 million from the European Commission to lead a European framework 7 (FP7) consortium of research and clinical groups (termed MABSOT*) in the advancement of clinical trials for its lead drug candidate OPN-305 in solid organ transplantation. A phase 1 trial in healthy volunteers is due to start this summer.
The Monoclonal Antibody Solid Organ Transplantation (MABSOT)* consortium which has been partially funded by the European Commission Seventh Framework Program (FP7) consists of Kings College London (UK), Katholieke Universiteit Leuven (Belgium), Fundacio Privada Institut D'Investigacio Biomedica De Bellvitge (Spain), Academisch Ziekenhuis Groningen (Netherlands), Institut Klinické a Experimentální Medicin (Czech Republic), University of Newcastle Upon Tyne (UK), Euram Ltd (UK) and Almac Diagnostics Ltd (UK), together with Opsona Therapeutics Ltd. (Ireland).
Therapeutic area: Transplantation
